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Abstract
Introduction: Respiratory muscle weakness is common in sepsis patients. Proinflammatory mediators produced
during sepsis have been implicated in diaphragmatic contractile dysfunction, but the role of chemokines has not
been explored. This study addressed the role of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2),
in the pathogenesis of diaphragmatic inflammation and weakness during endotoxemia.
Methods: Mice were treated as follows (n = 6 per group): (a) saline, (b) endotoxin (25 μg/g IP), (c) endotoxin +
anti-MCP-1 antibody, and (d) endotoxin + isotype control antibody. Muscles were also exposed to recombinant
MCP-1 in vivo and in vitro. Measurements were made of diaphragmatic force generation, leukocyte infiltration, and
proinflammatory mediator (MCP-1, IL-1a, IL-1b, IL-6, NF-B) expression/activity.
Results: In vivo, endotoxin-treated mice showed a large decrease in diaphragmatic force, together with
upregulation of MCP-1 and other cytokines, but without an increase in intramuscular leukocytes. Antibody
neutralization of MCP-1 prevented the endotoxin-induced force loss and reduced expression of MCP-1, IL-1a, IL-1b,
and IL-6 in the diaphragm. MCP-1 treatment of nonseptic muscles also led to contractile weakness, and MCP-1
stimulated its own transcription independent of NF-B activation in vitro.
Conclusions: These results suggest that MCP-1 plays an important role in the pathogenesis of diaphragmatic
weakness during sepsis by both direct and indirect mechanisms. We speculate that its immunomodulatory
properties and ability to modify skeletal muscle function make MCP-1 a potential therapeutic target in critically ill
patients with sepsis and associated respiratory muscle weakness.
Introduction
Sepsis is a major risk factor for the development of criti-
cal illness myopathy [1], and impaired skeletal muscle
function has been directly linked to systemic infections in
humans [2]. The diaphragm is the primary muscle of
respiration, and acute respiratory failure occurs in a large
proportion of patients with severe sepsis [3]. Major losses
of diaphragmatic force-generating capacity have been
documented in several different sepsis models [4-7].
Substantial data link this decreased diaphragmatic func-
tion to the associated systemic inflammatory response
syndrome (SIRS) and to the local expression of proin-
flammatory mediators (for example, reactive oxygen spe-
cies, nitric oxide, cytokines) within skeletal muscle fibers
(see reference [8] for recent review). Interestingly, evi-
dence also indicates that the diaphragm is particularly
prone to exaggerated proinflammatory gene upregulation
and impaired force production during different forms of
enhanced systemic inflammation [7,9,10].
Monocyte chemoattractant protein (MCP)-1, also
known as CCL2, is a prototypical member of the CC
subfamily of chemokines [11]. High serum levels of
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sepsis or SIRS [12-15], as well as in sepsis patients [16].
In a recent study profiling a large number of cytokines
in the plasma of patients with severe sepsis, MCP-1
levels showed the best correlation with organ dysfunc-
tion and mortality [17]. MCP-1 is primarily a chemoat-
tractant for monocytes, memory T lymphocytes, and
natural killer cells, with some recent studies also point-
ing to a potential role in attracting neutrophils [11,18].
However, it is important to recognize that the actions of
MCP-1 extend well beyond leukocyte chemoattraction.
In particular, MCP-1 has important effects on the bal-
ance between pro- and anti-inflammatory cytokines
[13,19,20]. In addition, MCP-1 exposure can lead to
increased insulin resistance in skeletal myocytes [21]
and also affects muscle repair mechanisms [22,23], sug-
gesting a potential to significantly modify muscle func-
tion in critically ill patients.
In the present study, our principal objective was to
determine whether MCP-1 is involved in the pathogen-
esis of diaphragmatic dysfunction associated with SIRS
induced by endotoxin administration. Our principal
aims were as follows: (a) to evaluate whether endotoxin
administration leads to increased MCP-1 expression in
skeletal muscles; (b) to assess whether an increased
exposure to MCP-1 has direct effects on skeletal muscle
function; and (c) to determine whether MCP-1 neutrali-
zation is able to modulate proinflammatory mediator
expression and contractile function in the diaphragm
during acute endotoxemic sepsis.
Materials and methods
Animal experiments
Experiments were performed in 8- to 10-week-old male
C57BL/6 mice (Charles River Laboratories, Saint-
Constant, QC, Canada). All procedures were approved
by the institutional animal care and ethics committee, in
accordance with the guidelines issued by the Canadian
C o u n c i lo nA n i m a lC a r e .T h em i c ew e r ea n e s t h e t i z e d
with a mixture of ketamine (130 μg/g) and xylazine (20
μg/g) prior to sacrifice.
Sepsis model
Mice were injected intraperitoneally with either Escheri-
chia coli endotoxin (LPS, serotype 055:B5) (25 μg/g) or
an equivalent volume of saline. Mice were sacrificed at
12 hours (unless specifically stated otherwise) after
administering LPS, and the muscles (diaphragm, exten-
sor digitorum longus (EDL), tibialis anterior) and other
tissues (lungs, liver, blood) were removed for the various
biochemical, histologic, and physiological analyses
described later in detail. For all MCP-1 neutralization
studies, the mice were pretreated with intraperitoneal
injection of an anti-MCP-1 neutralizing antibody (1 μg/
g) (BD Biosciences, San Diego, CA) at 12 and 24 hours
before LPS administration; this antibody and dose have
previously been shown to be effective in mice with sep-
tic peritonitis [14]. Control animals received the same
dose of an irrelevant isotypic control immunoglobulin,
administered in the same manner.
Local administration of MCP-1
To test the effects of exogenous MCP-1 on skeletal
muscle contractility, recombinant murine MCP-1 (100
pg in 10 μl of saline) (R&D systems, Minneapolis, MN)
was directly injected into the EDL muscle of the hin-
dlimb. The contralateral EDL was injected with an iden-
tical volume of saline at the same time to serve as a
within-animal control group, thereby eliminating any
potential differences related to systemic absorption of
the injected MCP-1. Both EDL muscles were surgically
exposed to ensure an accurately placed injection, and
after wound closure with sutures, the animals emerged
from anesthesia and resumed normal behavior. Mice
were sacrificed at 12 hours after administering MCP-1,
and both EDL muscles were removed.
Cell culture experiments
To evaluate the direct effects of MCP-1 on cytokine
expression by diaphragmatic muscle cells, primary dia-
phragmatic muscle cell cultures were established [9] by
using single living muscle fibers to isolate myoblast pre-
cursors (satellite cells). In brief, excised diaphragm mus-
cle strips were subjected to collagenase digestion and
trituration to liberate individual fibers. The individual
fibers were transferred into Matrigel-coated (Becton
Dickinson, Franklin Lakes, NJ) plates. Diaphragmatic
myoblasts were expanded in growth medium (20% fetal
bovine serum, 10% horse serum, 1% chick embryo
extract in DMEM) until attaining approximately 75%
confluence. The cultures were then placed in differentia-
tion medium (2% fetal bovine serum, 10% horse serum,
0.5% chick embryo extract in DMEM) to induce myo-
blast fusion into differentiated myotubes. All experi-
ments were performed on day 5 of maintenance in
differentiation medium. Diaphragmatic myotubes were
washed with DMEM before stimulation with recombi-
nant murine MCP-1 (100 ng/ml).
To determine the effects of MCP-1 on NF-B activity
in muscle cells, myoblasts were simultaneously trans-
fected with a NF-B-driven firefly luciferase reporter
plasmid (pNF-B; Clontech, Mountain View, CA) and a
constitutively active thymidine kinase promoter-driven
Renilla luciferase plasmid (pRL-TK; Promega, Madison,
WI), as previously described [24]. In this system, the
constitutively active Renilla luciferase serves as an inter-
nal control to adjust for any differences in transfection
efficiency. For these studies, we used the C2C12 skeletal
muscle cell line (ATCC, Manassas, VA) rather than pri-
mary skeletal muscle cells, as the latter are known to be
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C2C12 myoblasts (5 × 10
5) were seeded onto 60-mm
plates and transfected the following day at approxi-
mately 50% confluence, by using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). On day 5 in differentiation
medium, the cells were stimulated with murine MCP-1
(100 ng/ml) (R&D Systems, Minneapolis, MN), and the
activity levels of both forms of luciferase (firefly and
Renilla) were quantified by using the Dual-Luciferase
Reporter Assay System (Promega). Light emission was
measured in an Lmax 384 luminometer (Molecular
Devices, Downingtown, PA), and the results are
expressed as the ratio of firefly (reflecting NF-B activ-
ity) to Renilla luciferase activities in relative light units.
Analyses of protein and mRNA expression
A commercial ELISA kit for murine MCP-1 (R&D Sys-
tems, Minneapolis, MN) was used to measure serum
and tissue MCP-1 protein levels in duplicate, according
to the manufacturer’s instructions. Serum was collected
by cardiac puncture, and total protein was extracted
from the diaphragm, tibialis anterior, liver, and lung.
Frozen tissue samples were homogenized in lysis buffer
(1% Triton X-100, 50 mM HEPES (pH 8.0), 150 mM
NaCl, 10% glycerol, 2 mM EDTA, 1.5 mM MgCl2,1 0
μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM phenyl-
methylsulphonyl fluoride, 1 mM sodium orthovanadate).
Homogenates were centrifuged 10 minutes at 10,000
rpm, and the supernatant protein content measured
with Bradford assay (BioRad Laboratories, Hercules,
CA).
To measure mRNA expression levels of MCP-1 and
its receptor CCR2, IL-1a,I L - 1 b,a n dI L - 6 ,t o t a lR N A
from tissue or cell cultures was extracted by using Tri-
zol reagent (Invitrogen) according to the manufacturer’s
protocol.
32P-labeled, anti-sense RNA probes were
synthesized from commercially available Multi-Probe-
Template sets (BD Biosciences, San Diego, CA). Ribop-
robes were hybridized overnight at 56°C with 10 μgo f
sample RNA, according to the manufacturer’si n s t r u c -
tions. Protected RNA fragments were separated by using
a 5% polyacrylamide gel and analyzed with autoradiogra-
phy. For each RNA probe, all experimental groups were
run on a single gel to allow quantitative comparisons.
The bands representing mRNA content were quantified
by using an image-analysis system (FluorChem 8000;
Alpha Innotech, San Leandro, CA), and the signals nor-
malized to the L32 housekeeping gene as a loading
control.
Analyses of leukocyte infiltration
To quantify macrophages and neutrophils, skeletal mus-
cle cryosections (5 μm thick) were reacted with mono-
clonal antibodies directed against either macrophage F4/
80 (1:75 dilution) (Abcam, Cambridge, MA) or neutro-
phil Ly-6G (1:50 dilution) (BD Biosciences). Nonspecific
binding sites were blocked by incubating sections for 1
hour with PBS containing 3% BSA and 5% goat serum,
followed by goat anti-mouse IgG Fab fragment (1:20
dilution) (Jackson Laboratories, West Grove, PA) for 30
minutes. Biotinylated rabbit anti-rat IgG secondary anti-
body (1:100 dilution) (Vector Laboratories, Burlingame,
CA) was added and revealed by using the Vectastain
streptavidin-HRP system (Vector Laboratories) with
DAB substrate (Sigma-Aldrich Canada, Oakville, ON,
Canada). To quantify inflammatory cell infiltration, the
central and adjacent 20 × fields of the tissue were
photographed by using a digital camera, and a stereol-
ogy software package (Image-Pro Plus; Media Cyber-
netics, Silver Spring, MD) was used to overlay a
275-point grid onto each image (six photographs per
muscle). Inflammatory cells were quantified by using a
standard point-counting method, in which an abnormal
point was defined as falling either on an inflammatory
cell or on a myofiber invaded by such cells. The percen-
tage area of inflammation was then calculated by divid-
ing the number of abnormal points by the total number
of points falling on the muscle tissue section [26]. The
muscle images were selected in random order, with the
operator blinded to the identity of the experimental
groups.
As an additional index of neutrophil activity within
tissues, myeloperoxidase (MPO) activity was determined
[27]. In brief, frozen tissues were homogenized in 1 ml
ice-cold 50 mM potassium phosphate buffer at pH 6.0.
Homogenates were centrifuged at 12,000 g for 15 min-
utes at 4 degrees Celsius, and the supernatant was dis-
carded. Pellets were resuspended, homogenized,
centrifuged, and the pellets were resuspended in buffer.
Assays were performed in duplicate on supernatant
added to buffer containing 0.167 mg/ml o-dianisidine
and 0.0005% H2O2. Enzymatic activity was determined
spectrophotometrically by measuring the change in
absorbance at 460 nm over a 3-minute period. Values
are expressed as units per gram of tissue, with each unit
representing the change in optical density per minute.
Muscle contractile function
The diaphragm or EDL muscle was surgically excised
for in vitro contractility measurements, as previously
described [7,28]. Muscles from the different experimen-
tal groups were selected in random order, with the indi-
vidual performing the contractility measurements being
blinded to their identity. After removal from the animal,
muscles were transferred into Krebs solution (118 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2,1 . 2m M MgSO4,1
mM KH2PO4,2 5m M NaHCO3,a n d1 1m M glucose)
chilled to 4°Celsius and perfused with 95% O2/5% CO2
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tissue-bath chamber filled with continuously perfused
Krebs solution warmed to 25°Celsius. After a 15-minute
thermoequilibration period, muscle length was gradually
adjusted to optimal length (Lo, the length at which max-
imal twitch force is obtained). The force-frequency rela-
tion was determined by sequential supramaximal
stimulation for 1 second at 5, 10, 20, 30, 50, 100, 120,
and 150 Hz, with 2 minutes between each stimulation
train. At the end of the experiment, Lo was directly
measured with a microcaliper and the muscle blotted
dry and weighed. Specific force (force/cross-sectional
area) was calculated, assuming a muscle density of 1.056
g/cc and expressed in N/cm
2.
Statistical analysis
All data are presented as mean values ± SD (n =6p e r
group). Group mean differences were determined with
Student’s t test, or with one-way or two-way ANOVA
with post hoc application of the Tukey test to adjust for
multiple comparisons. A statistics software package was
used for all analyses (SigmaStat V2.0; Jandel Scientific,
San Rafael, CA). Statistical significance was defined as
P < 0.05.
Results
Effects of sepsis on MCP-1 expression and inflammatory
cells in the diaphragm
To evaluate mRNA expression levels of MCP-1, dia-
phragms from saline and LPS groups of mice were
analyzed with RNase protection assay, as shown in
Figure 1a. MCP-1 mRNA was not detected in control
diaphragms, but was greatly increased in the diaphragms
of septic animals (Figure 1b). Conversely, expression
levels of CCR2, the only known receptor for MCP-1,
were downregulated in the diaphragm after LPS admin-
istration (Figure 1c). The upregulation of MCP-1 mRNA
transcript levels was associated with a similar increase in
MCP-1 protein content within the septic diaphragm, as
shown in Figure 2a. MCP-1 protein levels were also
found to be significantly elevated in the serum (Figure
2b), as well as in the lung, liver, and the tibialis anterior
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Page 4 of 11muscle (Figure 2c) of LPS-group animals. Interestingly,
MCP-1 protein levels were two- to threefold higher in
the diaphragm than in the hindlimb muscle (tibialis
anterior) under septic conditions.
To determine whether the augmented levels of MCP-1
detected in the septic diaphragm were associated with
increased leukocyte infiltration into the muscle, immu-
nohistochemical analysis was performed with antibodies
directed against markers for macrophages and neutro-
phils. As shown in Figure 3, no measurable differences
between control and septic diaphragms were found in
the numbers of either leukocyte population. This was
further confirmed for the neutrophil population by the
lack of change in diaphragmatic MPO activity, whereas
MPO activity was greatly increased in the lungs of septic
animals (Figure 3f).
Effects of MCP-1 on skeletal muscle proinflammatory
markers in vivo and in vitro
The ability of MCP-1 to modulate proinflammatory
cytokine gene expression in the diaphragm during sepsis
in vivo was investigated by pretreating animals with
anti-MCP-1 neutralizing antibody. As indicated in Fig-
ure 4, transcript levels for IL-1a,I L - 1 b,a n dI L - 6 ,a s
well as for MCP-1 itself, were all significantly lower in
the diaphragms of mice that were pretreated with the
MCP-1 neutralizing antibody before LPS administration.
Therefore, systemic blockade of endogenous MCP-1
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proinflammatory genes in the septic diaphragm.
We next sought to determine whether MCP-1 is cap-
able of directly stimulating inflammatory responses in
primary diaphragmatic muscle cell cultures examined at
4, 8, and 16 hours after stimulation. Interestingly,
despite significant effects of MCP-1 neutralization on
the expression of these genes in the septic diaphragm
in vivo, the transcript levels of IL-1a,I L - 1 b,a n dI L - 6
were unaltered by direct MCP-1 stimulation of skeletal
muscle cells in vitro (no detectable expression under
either unstimulated or stimulated conditions). As shown
in Figures 5a and 5b, only MCP-1 itself was significantly
upregulated by MCP-1 stimulation in diaphragmatic
muscle cells, and this effect was noted at 8 hours after
stimulation. Moreover, in keeping with the fact that
MCP-1 did not upregulate these classic proinflammatory
genes in primary muscle cell cultures, we also did not
find any significant influence of MCP-1 treatment on
the NF-B transcriptional activity assay in C2C12 skele-
tal muscle cells (Figure 5c). Taken together, these results
suggest that MCP-1 is capable of acting on skeletal
muscle cells to upregulate its own expression, but in a
manner not dependent on NF-B pathway activation.
Effects of MCP-1 on skeletal muscle contractile function
in vivo
To evaluate the potential contribution of MCP-1 to the
adverse effects of sepsis on the contractile function of
skeletal muscles, two different approaches were used.
First, to determine whether direct exposure of skeletal
muscle fibers to MCP-1 has effects on contractile func-
tion, recombinant MCP-1 protein was injected into the
EDL muscle. The dose of MCP-1 administered to the
EDL was extrapolated from the diaphragmatic MCP-1
content (picograms per muscle weight) at 12 hours after
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Page 6 of 11LPS administration, as determined with ELISA and pre-
sented earlier in Figure 2. Figure 6a shows that at 12
hours after injection of recombinant MCP-1 into the
EDL, a small but statistically significant reduction was
noted in the force-generating capacity of the MCP-1-
injected EDL muscles relative to the contralateral con-
trol (saline-injected) muscles from the same animals.
Furthermore, as was the case for septic diaphragms at
the same time point after LPS administration (12
hours), the MCP-1-injected EDL muscles did not show
any histologic evidence of inflammatory cell infiltration
(not detected in either saline- or MCP-1-injected
muscles).
Second, to determine whether MCP-1 plays a role in
diaphragmatic contractile dysfunction during sepsis, the
force-generating capacity of the diaphragm was com-
pared in animals pretreated with anti-MCP-1 neutraliz-
ing antibody versus an irrelevant isotype control
immunoglobulin. As expected, LPS administration led to
a major decrease in diaphragmatic force production 12
hours later. The LPS-induced depression of diaphrag-
matic force was unaffected by pretreatment with an irre-
levant isotype control antibody. In marked contrast, the
loss of diaphragmatic force production at 12 hours after
LPS administration was greatly alleviated in animals pre-
treated with anti-MCP-1 neutralizing antibody, as
illustrated in Figure 6b. These findings indicate that
MCP-1 plays a significant role in the impairment of dia-
phragmatic function associated with acute endotoxemic
sepsis.
Discussion
To our knowledge, this is the first study to examine spe-
cifically the role of a chemokine, MCP-1, in proinflam-
matory mediator production by the diaphragm and the
contractile dysfunction of the muscle that occurs during
sepsis. From a clinical standpoint, our most important
observation was that neutralization of MCP-1 greatly
alleviated diaphragmatic weakness in the setting of acute
endotoxemia. This was associated with significantly
diminished diaphragmatic expression of proinflamma-
tory cytokines. Previous investigations in animals have
shown that MCP-1 effects in sepsis can vary according
to cell type and experimental model, as well as the spe-
cific mode and timing of MCP-1 inhibition. For exam-
ple, in the cecal ligation/perforation (CLP) sepsis model,
mice genetically deficient in MCP-1 showed lower IL-10
production in peritoneal macrophages and increased
mortality [20]. In contrast, antibody neutralization of
MCP-1 in the CLP context had a beneficial effect on
survival [14], and the administration of an MCP-1-
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Page 8 of 11beneficial in different murine models of sepsis [29]. A
complex pattern of both pro- and anti-inflammatory
effects on different organs has been reported after
MCP-1 neutralization in CLP animals [13].
Intriguingly, in a recent prospective cohort study of
patients with severe sepsis in which a multiplex analysis
of 17 candidate cytokines in the serum was performed,
only MCP-1 was found to be independently associated
with increased mortality [17]. The fact that the dia-
phragm constitutively expresses CCR2 [30] led us to test
the hypothesis that MCP-1 could directly regulate the
expression of proinflammatory mediators in skeletal
muscle cells. In keeping with this, we found that direct
stimulation of primary diaphragmatic cell cultures by
purified MCP-1 led to an increase of MCP-1 transcripts,
suggesting the existence of positive-feedback autoregula-
tion. Such a feed-forward loop has been previously
described for other chemokines in different cell types
[31,32]. Although very little is known about the
mechanisms or functional significance of this positive-
feedback loop, the result is likely to be an enhancement
of MCP-1 actions. The downregulation of CCR2 expres-
sion that we observed in the septic diaphragm, which is
analogous to that reported in monocytes exposed to
LPS [33], is presumably an important mechanism for
counterbalancing this effect.
Interestingly, the transcript levels of IL-1a,I L - 1 b,a n d
IL-6 were unaltered by direct MCP-1 stimulation of skele-
tal muscle cells in vitro. Consistent with these findings,
NF-B reporter gene activity was also not increased in
myotubes exposed to MCP-1. Although it could be argued
that activation of NF-B may have occurred more rapidly
than the earliest time point examined in our study (4
hours), this appears unlikely because the firefly luciferase
protein used as a readout in these experiments is stable
for up to 6 hours in mammalian cells [34]. Furthermore,
in primary human abdominal muscle culture, MCP-1 did
not induce NF-B activation within 1 hour of stimulation
[21]. This is in contrast to the situation within isolated car-
diomyocytes, in which MCP-1 (at the same dose used in
our study) has been reported to upregulate IL-1b and IL-6
expression [19]. MCP-1 has also been found to stimulate
the expression of IL-6 in neutrophils [18] and leukotriene
B4 in peritoneal macrophages [12]. Taken together, these
findings emphasize the existence of cell- and organ-speci-
fic regulatory mechanisms for MCP-1. Furthermore, given
our demonstration that MCP-1 stimulation of skeletal
muscle cells in vitro fails directly to upregulate IL-1a, IL-
1b, or IL-6 expression, it is likely that the ability of MCP-1
neutralization to downregulate these cytokines in vivo dur-
ing sepsis is achieved, at least in part, via intermediary
partners.
Although MCP-1 was recently shown to play several
key roles in skeletal muscle repair and metabolism
[21-23,35], its influence on muscle function during sep-
sis has not been previously explored. We found that
in vivo neutralization of endogenous MCP-1 during
acute sepsis led to substantial decreases in the transcript
levels for IL-1a, IL-1b, and IL-6, as well as MCP-1 itself,
in the diaphragm. IL-1 significantly decreases muscle
weight, protein content, and the rate of protein synthesis
in skeletal muscle [36], whereas IL-6 can upregulate the
cathepsin and ubiquitin pathways of muscle proteolysis
[37]. Exposure of human skeletal muscle cells to MCP-1
at physiologic concentrations has been demonstrated to
induce a state of increased insulin resistance, as indi-
cated by alterations in insulin signaling with an asso-
ciated impairment of glucose uptake [21]. Taken
together, such metabolic derangements all have the
potential to depress skeletal muscle contractile function.
In addition, reactive oxidative species also play an
important role in diaphragmatic dysfunction during sep-
sis [8], and overproduction of MCP-1 has been linked to
increased oxidative stress and tissue damage in cardiac
muscle after ischemia-reperfusion [38].
As an important leukocyte chemoattractant molecule,
a plausible hypothesis was that MCP-1 overexpression
in the diaphragm during sepsis might increase inflam-
matory cell infiltration into the muscle. This was not
found to be the case, as the levels of both neutrophils
and macrophages in the diaphragm were unaffected by
LPS administration. In addition, although direct injec-
tion of MCP-1 into skeletal muscle was associated with
a mild reduction in force-generating capacity, this was
similarly not linked to increased inflammatory cell infil-
tration. However, this does not exclude the possibility
that increased exposure to MCP-1 (either during sepsis
in the diaphragm or through direct injection into the
EDL) modified the activation state of resident macro-
phages within these muscles, and this hypothesis
deserves further study.
Conclusions
In summary, this study demonstrates that the increased
endogenous MCP-1 production during SIRS induced by
endotoxin contributes to proinflammatory mediator pro-
duction by the diaphragm, along with a major decrease
in diaphragmatic force-generating capacity. Our findings
suggest that the systemic immunomodulatory properties
of MCP-1, coupled with its ability to modify skeletal
muscle cell function directly, could make MCP-1 an
attractive therapeutic target in sepsis patients, especially
in the setting of respiratory muscle dysfunction and ven-
tilatory failure.
Key messages
￿ MCP-1 is significantly upregulated in the dia-
phragm during acute endotoxemic sepsis
Labbe et al. Critical Care 2010, 14:R187
http://ccforum.com/content/14/5/R187
Page 9 of 11￿ Antibody neutralization of MCP-1 in this setting
reduces the diaphragmatic expression levels of sev-
eral proinflammatory cytokines that have been impli-
cated in the pathogenesis of sepsis
￿ MCP-1 neutralization prevents the loss of dia-
phragmatic force-generating capacity normally
observed during acute endotoxemia
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